Sam Brusco, Associate Editor03.02.23
Boomerang Medical, a women-led bioelectronic medicine company, was granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its bioelectronic tech targeting treatment of inflammatory bowel disease (IBD).
Current IBD treatments include drugs, biologics, nutrition, physical therapy, and behavioral health therapy. Researchers participating in the Boomerang IBD trial are evaluating the potential of bioelectronic medicine to stimulate the body’s parasympathetic nervous system to decrease stress on the body and reduce inflammation.
“Living with IBD affects every facet of life,” Heather Simonsen, president and CEO of Boomerang Medical told the press. “Unfortunately, there are millions of Americans of all ages currently suffering from Crohn’s disease and ulcerative colitis. As the rate of IBD continues to increase, we are committed to generating clinical evidence for this innovative bioelectronic therapy to diversify the treatment options for IBD.”
Boomerang is enrolling patients in a single-arm pilot study at IBD centers in NYC, Charleston, Houston, Wichita, and Philadelphia, with more sites to be added in the future. The study allows for patients diagnosed with Crohn’s disease and ulcerative colitis who may or may not have previously exposed to biologic therapy.
Current IBD treatments include drugs, biologics, nutrition, physical therapy, and behavioral health therapy. Researchers participating in the Boomerang IBD trial are evaluating the potential of bioelectronic medicine to stimulate the body’s parasympathetic nervous system to decrease stress on the body and reduce inflammation.
“Living with IBD affects every facet of life,” Heather Simonsen, president and CEO of Boomerang Medical told the press. “Unfortunately, there are millions of Americans of all ages currently suffering from Crohn’s disease and ulcerative colitis. As the rate of IBD continues to increase, we are committed to generating clinical evidence for this innovative bioelectronic therapy to diversify the treatment options for IBD.”
Boomerang is enrolling patients in a single-arm pilot study at IBD centers in NYC, Charleston, Houston, Wichita, and Philadelphia, with more sites to be added in the future. The study allows for patients diagnosed with Crohn’s disease and ulcerative colitis who may or may not have previously exposed to biologic therapy.